Oxford Science Enterprises
To add a bio or update investment portfolio, please click update information.
Investment Portfolio


Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs
Allos AI applies causal AI to reformulate complex generic drugs, improving delivery, tolerability and predictability while reducing development uncertainty.


Scripta Therapeutics raises £9m seed led by Oxford Science Enterprises and Apollo Health Ventures to upend conventional drug discovery
Scripta Therapeutics applies AI and experimental biology to map disease-driving transcription networks, aiming to identify new drug targets for neurodegenerative and complex conditions.


Wild Bio secures £45m Series A led by the Ellison Institute of Technology to boost crop resilience by learning from wild species
Wild Bio applies AI and precision breeding to crop genetics, using insights from wild plant species to develop climate-resilient, higher-yield crop varieties for commercial agriculture.


Kneu Health raises £4m seed round co-led by Oxford Science Enterprises and Cedars-Sinai to scale precision neurology platform
Kneu Health develops a precision neurology platform that uses smartphone-based data and clinically trained AI models to monitor Parkinson’s and dementia continuously, supporting earlier intervention and more proactive neurological care.


Ultromics raises £40m Series C led by L&G, Allegis Capital and Lightrock to expand AI heart failure diagnostics in the US
Ultromics develops AI software that analyses echocardiograms to help clinicians detect hard-to-diagnose heart failure conditions earlier, without requiring new hardware or changes to existing clinical workflows.


NavLive raises £4m seed round led by OSE to launch real-time AI scanner for architecture and construction
NavLive develops a handheld AI-powered scanning device that creates real-time, high-precision building surveys, enabling architects and construction teams to generate instant 2D and 3D models on site.


Neu Health raises £1.6m from Cedars-Sinai and Oxford Science Enterprises to expand neurology care platform
Neu Health provides a digital care platform for neurological conditions, enabling continuous patient monitoring and personalised care plans to support people living with Parkinson’s and dementia.
More venture news
- 2 Mar 2026


Ivee raises a seven-figure seed round from Social Impact Enterprises and angels for AI upskilling and talent platform
SeedHR - 25 Feb 2026


Kinfolk raises a £5m seed round led by AlbionVC to shift manual HR workflows with agentic AI
SeedHR - 25 Feb 2026


BeyondMath secures a £14m seed round led by Cambridge Innovation Capital to run engineering-grade simulations faster with AI model
SeedDeep Tech